

Case report

Double Primary Tumors: Synchronous of Prostate cancer and Rectum cancer. A case report

ABSTRACT

Multiple primary tumors (MPT) defined as the development of 2 or more tumors with different histology characteristic which arise from different organ and metastasis must be excluded. MPT can divide to synchronous or metachronous. Prostate cancer with synchronous rectal cancer are rarer compared to metachronous. The synchronous prostate cancer is commonly found in either the renal or urinary bladder. We are reporting a case of 66 years old gentleman who was diagnosed with prostate cancer with synchronous rectum cancer. Decision making in managing is rather be challenging as there are two separate entities and have a different approach for both surgical and oncology treatment.

Keywords: Synchronous; prostate; rectum; multiple primary tumors; neoplasm.

1. INTRODUCTION

Prostate cancer and colorectal cancer are the top two commonest cancer in the world (14.8% and 9.2% respectively).¹ Both prostate and colorectal cancer may co-exist either synchronous or metachronous. However, the incidence of multiple primary tumors (MPT) are low between 5% to 8% of all cancer.² Prostate cancer and synchronous rectal cancer are uncommon. The effectiveness of cancer therapy together with aging population have increase the challenge of managing MPT. The validity of treating both primary tumors must be questioned on an individual patient basis. Here, we are reporting a case of 66 years old gentleman with double primary tumors and discuss regarding decision making on both surgical and oncology treatment.

2. CASE PRESENTATION

A 66 years old gentleman with underlying hypertension, dyslipidemia and chronic kidney disease (CKD) was diagnosed with double primary tumors; T1cN0M0 prostatic adenocarcinoma (Gleason Score 3+4, intermediate risk group) and T3N0M0 rectal adenocarcinoma.

He initially presented with lower urinary tract symptoms for 1 years and was diagnosed with benign prostatic hypertrophy with IPSS 29 and QOL 3. His symptoms improved and well controlled with a single therapy. During follow-up, noted his prostate-specific antigen (PSA) was high, 7. However, he has no red flag symptoms and signs of prostate cancer. Trans-rectal ultrasound (TRUS) guided biopsy of the prostate gland was done on Jan 2018 and HPE showed no malignancy seen in all 6 cores of biopsy. Since then, he was on 6 monthly follow-up.

On Oct 2019, during his subsequent follow-up, noted his PSA was increasing in trend from 7 to 12.8 and his digital rectal examination (DRE) was T1c. TRUS biopsy, bone scan and magnetic resonance imaging (MRI) of prostate were arranged to confirm the diagnosis. TRUS biopsy taken with a total of 15 cores ; 4 cores out of 6 cores on the left side were confirm prostate adenocarcinoma with Gleason score 7 (3+4) while 9 cores on the right side no malignant seen. No evidence metastasis on bone scan. MRI prostate shown segmental T2 hypointensity on the left apex peripheral zone with the capsular breach (PIRADS 5) and moderate hypointensity on left mid gland transition zone (PIRADS 4). On right lobe, segmental T2 moderate hypointensity on right apex peripheral zone (PIRADS 4) and right mid-gland transition zone (PIRADS 5). No extraprostatic extension to the neurovascular bundle , seminal vesicles, lymph node and bone. However, noted incidental findings of mid and lower rectal mass with a clear plane to prostate and seminal vesicles.

Colorectal workup ensued. Further history taking revealed, he was having on and off per rectal bleeding with tenesmus for 6 months. DRE revealed mass 4cm from the anal verge. Laboratory investigation shown carcinoembryonic antigen (CEA) not elevated at 5.9ng/mL. Colonoscopy with biopsy was done shown fungating mass 4cm from anal verge and HPE confirm rectal adenocarcinoma with local invasion beyond muscularis propria (T3).



Fig. 1. Fungating rectal tumor findings on colonoscopy

He was seen by a urologist, colorectal surgeon and oncologist and multidisciplinary team discussion was done. Few options were discussed ; 1) total neoadjuvant therapy for rectal cancer followed by robotic-assisted radical prostatectomy (RARP) and ultra-low anterior resection with defunctioning ileostomy (ULAR) 2) Long course CCRT(45 Gy/25 F for 5 weeks with 5-fluorouracil and capecitabine) for rectal followed by surgery (RARP + ULAR) 3) ULAR + RARP. The oncology recommended for option 2 in view of underlying CKD. He was then underwent combined surgery 6 weeks post-CCRT. Post-surgery was uneventful. Histopathology examination (HPE) of the prostate gland have showed left prostatic adenocarcinoma is confined within prostatic capsule with involvement of half of the lobe (T2a). While HPE of the colon (anterior resection) shown complete resection of rectal adenocarcinoma with local invasion beyond the muscularis propria and no lymphovascular invasion (T3N0, Duke B). The malignant tumor positive towards CK20, CDX 2 and negative for CK7 and PSA.




Fig 2 (a and b) : Histopathology of Adenocarcinoma of the prostate. Figure 2a: Malignant glands (x) infiltration with adjacent benign prostate gland(x). Figure 2b: Malignant glands are closely packed, lined by malignant cells with prominent nucleoli.




Fig 3(a and b): Histopathology of Adenocarcinoma of the rectum. Figure 3a: The colonic mucosa is infiltrated by crowded, irregular and tortuous malignant gland. Figure 3b: The gland are lined by malignant cells exhibiting hyperchromatic and pleomorphic nuclei.

3. DISCUSSION

Prostate and colorectal cancer are two common cancers in male. MPT are rare but the incidence detection of MPT are increasing. This is the consequence of improved clinical awareness, increase cancer survivor, advances in diagnostic technology, a change of lifestyle with a diet and an increase of life span that allow patients to develop more than one primary cancer.

Billroth (1889) defined MPT as development of 2 or more tumors in the same person with different histological characteristics, arising from different organs, and presenting with their own metastatic deposits.⁶ In 1932, the definition was modified by Warren and Gates as 2 or more malignancies have different histological characteristics, and metastasis must be excluded.⁷ MPTs are divided into 2; synchronous and metachronous. Synchronous MPTs are present of 2 or more tumors diagnosed within 6 months, while metachronous MPTs are present 2 or more tumors diagnosed with a time interval >6 months. In this case, synchronous rectal tumor detected same time during investigation of diagnosing prostate cancer on MRI of prostate.

Older age group being a higher risk of developing second primary tumor. Spratt and Hoag ⁷ reported that person living to extreme age expected to have multiple cancer with greater frequency. Several review

reported that more than 75% with MPT more than 50 years old age and most neoplasm with MPTS involve respiratory, gastrointestinal and genitourinary systems. [4,5,8,9,10](#)

The synchronous disease is rarer than metachronous rectal and prostate cancer. Elmi et al reported 5.9 % synchronous tumor detected during initial staging workout and most common second primary tumor is kidney(1.97%) followed with lymphoma (1.13%) [11](#). Similar to Ozsoy et al,[12](#) they found that only 1.2% of patients with prostate cancer detected synchronous tumor and most secondary primary tumor are kidney and bladder. The incidence of synchronous rectal tumor is less than 1%.[12](#) In synchronous disease, accurate CT and MRI staging is crucial to evaluate both malignancies to reduce the chance of unnecessary radical surgery. In this case report, MRI showed there are separate entities as there are clear plane between the rectal mass and prostate and rectal mass does not extend to muscularis propria. HPE of both tumor also confirmed two primary tumors ; prostate adenocarcinoma (T2a) and rectal adenocarcinoma (T3No, Duke B).

The treatment of synchronous tumors depend on each primary tumor staging. There were no issue in managing the early stage of synchronous tumors as neoadjuvant are not indicated. The difficulties in treatment are greatest when both tumors are locally advanced and particularly when the rectal cancer lies in the mid or lower rectum. In this case, the patient is diagnosed with the locally advanced rectal carcinoma stage III (T3N0M0) and has intermediate-risk of prostate cancer

Prostate cancer is a complex disease in which disease characteristics, age, comorbidities and individual preference will impact treatment of choice. Patient should be stratified by PSA, clinical stage, Gleason score, volume of disease on biopsy and radiological stage. Options include active surveillance, intervention with curative intent, androgen deprivation therapy (ADT) and brachytherapy. As stated previously, EAU recommends that radical prostatectomy (RP) with curative intent should be offered to all men with intermediate-risk disease: PSA 10-20ng/ml, Gleason score 7, clinical stage T2b. Extended pelvic lymph node dissection (ePLND) should be performed if the estimated risk of positive lymph nodes exceed 5%. Low-dose-rate (LDR) brachytherapy or external beam radiation therapy (EBRT) are strongly recommended for patient with localised disease with intermediate risk.

The role of neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer (LARC) is well established and results in reduced local recurrence compared to surgery alone. Traditionally, LARC patients will offer for long course CCRT followed with surgery and adjuvant therapy [13](#). However, the latest trial by Van der Valk et al (RAPIDO trial) suggests short-course radiotherapy followed by chemotherapy and delayed surgery with the aim to reduce distant metastases without compromising locoregional control.[14](#)

The differing dosage regimens and irradiation fields used in the treatment of rectal and prostate cancer pose a particular challenge as the lower dose used in rectal cancer would be considered subtherapeutic for prostate cancer, while the higher dose used in the definitive treatment of prostate cancer could increase the technical difficulty of low anterior resection and the risks of anastomotic failure. Besides that, comorbidities and functional status of patient also need be consider prior commencing chemoradiotherapy due to the toxicities.[15,16](#) In this case, total neoadjuvant therapy is not suitable in view of underlying renal impairment.

4. CONCLUSION

Synchronous detection of prostate cancer associated with rectum cancer is uncommon, but it should be forgotten. It can be detected by increase with the rigorous preoperative staging of prostate cancer and increased awareness of the potential for synchronous disease. Besides that, the existence management of first cancer did not influence the treatment or outcome of second cancer. Treatment must be individualized taking into account a patient's symptoms and the stage of the individual cancers.

REFERENCES

1. Ferlay J., Soerjomataram I., Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E386.
2. Alonso, M.M. & Gelabert, Antoni. (2010). Independent multiple primary tumors and second primary neoplasms. Relationship between smoking. *Actas urológicas españolas*. 34. 516-21. 10.1016/S2173-5786(10)70123-2. Koubková L, Hrstka R, Dobes P, Vojtesek B, Vyzula R. Second primary cancers - causes, incidence and the future. *Klin Onkol*. 2014;27(1):11-7. doi: 10.14735/amko201411. PMID: 24635432.
3. Hadju SI, Hadju EO. Multiple primary malignant tumors. *J Am Geriatr Soc* 1968; 16: 16–26
4. Berge T, Cederqvist L, Schonebeck J. Multiple primary malignant tumors: an autopsy study of a circumscribed population. *Acta Pathol Microbiol Scand* 1969; 76: 171–183.
5. Billroth T. General surgical pathology and therapy. Guidance for students and physicians. *Khirurgiia (Mosk)* 1991:136–43
6. Warren S, Gates O. Multiple primary malignant tumors-a survey of the literature and statistical study. *Am J Cancer* 1932;16:1358–414.
7. Spratt JS, Hoag MG. Incidence of multiple primary cancers per man-year of follow up: 20-year review from the Ellis Fischel State Cancer Hospital. *Ann Surg* 1966; 164: 775–784
8. Office for National Statistics *Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England*. Newport: ONS; 2010
9. Demandante, Carlo Greg N.; Troyer, Dean A., M.D.; Miles, Toni P., M.D., Ph.D. Multiple Primary Malignant Neoplasms, *American Journal of Clinical Oncology*: February 2003 - Volume 26 - Issue 1 - p 79-83
10. Elmi A, Tabatabaei S, Talab SS, Hedgire SS, Cao K, Harisinghani M. Incidental findings at initial imaging workup of patients with prostate cancer: clinical significance and outcomes. *AJR Am J Roentgenol*. 2012 Dec;199(6):1305-11. doi: 10.2214/AJR.11.8417. PMID: 23169722.
11. Ozsoy O, Fioretta G, Ares C, Miralbell R. Incidental detection of synchronous primary tumours during staging workup for prostate cancer. *Swiss Med Wkly*. 2010 Apr 17;140(15-16):233-6. PMID: 20407958.
12. Rödel C, Martus P, Papadopoulos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *J Clin Oncol*. 2005;23(34):8688-8696. doi:10.1200/JCO.2005.02.1329
13. van der Valk MJM, Marijnen CAM, van Etten B, et al; Collaborative investigators. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer: results of the international randomized RAPIDO-trial. *Radiother Oncol*. 2020;147:75-83. doi:10.1016/j.radonc.2020.03.011
14. Dudani, Shaan & Marginean, Horia & Powell, Erin & Vickers, Michael & Cheung, Winson & Kennecke, Hagen & Babak, Sam & Dennis,, Kristopher & Monzon, Jose & Tang, Patricia & Gotfrit, Joanna. (2018). The impact of chronic kidney disease in locally advanced rectal cancer patients treated with neoadjuvant chemoradiation.. *Journal of Clinical Oncology*. 36. 10.1200/JCO.2018.36.4_suppl.794.
15. Takimoto, C. H., Remick, S. C., Sharma, S., Mani, S., Ramanathan, R. K., Doroshow, J. H., Hamilton, A., Mulkerin, D., Graham, M., Lockwood, G. F., Ivy, P., Egorin, M., Greenslade, D., Goetz, A., & Grem, J. L. (2003). Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group. *Seminars in oncology*, 30(4 SUPPL. 15), 20-25. [https://doi.org/10.1016/S0093-7754\(03\)00401-9](https://doi.org/10.1016/S0093-7754(03)00401-9)